Tuten et al., 2012 - Google Patents
The role of significant others and family members in substance abuse treatment.Tuten et al., 2012
- Document ID
- 9494527499308363537
- Author
- Tuten L
- Jones H
- Schaeffer C
- Stitzer M
- Publication year
External Links
Snippet
The majority of adults who have substance use disorders report having a significant other. Because significant others and family members can serve as powerful influences in either helping a client maintain abstinence from drugs or setting the occasion for substance use …
- 201000009032 substance abuse 0 title abstract description 5
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saxena et al. | World Health Organization's Comprehensive Mental Health Action Plan 2013–2020. | |
| HK1223319A1 (en) | Methods for treating or preventing ophthalmological conditions | |
| MX2016000220A (en) | Regulation of glucose metabolism using anti-cgrp antibodies. | |
| Tuten et al. | The role of significant others and family members in substance abuse treatment. | |
| EA201591603A1 (en) | NEW THERAPEUTIC COMBINATIONS MYRTAZAPINE FOR APPLICATION IN PAIN DISEASES | |
| Burton | Should your patient be doing yoga? | |
| Ifekandu et al. | The cost‐effectiveness in the use of HIV counselling and testing‐mobile outreaches in reaching men who have sex with men (MSM) in northern Nigeria | |
| WO2013137912A3 (en) | Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor | |
| WO2012145234A3 (en) | Cyclopropyl derivatives and methods of use | |
| WO2015051279A3 (en) | Cxcr4 up- and down-regulation for treatment of diseases or disorders | |
| Tuten et al. | The atmosphere of treatment delivery. | |
| Balhara | A chart review based comparative study of retention rates for two dispensing regimens for buprenorphine for subjects with opioid dependence at a tertiary care substance use disorder treatment center | |
| Palmero | Certificate of Participation | |
| Dyer | Widow of man who fought for right to die can continue his case | |
| Marengoni et al. | Mental health and the global agenda: Comment. | |
| Kuukasjarvi | " Me in my body"-experience for adult group therapy with bodily symptoms | |
| Forand et al. | Antidepressant controversy: A cause for concern and an opportunity for progress. | |
| Cherian | Status epilepticus: case report | |
| McDaniel et al. | Community engagement. | |
| Tuten et al. | The feedback session: An adaptation of motivational interviewing. | |
| Stith et al. | Our research findings. | |
| Bryn | Federal partners in bullying prevention | |
| Wang | Benzathine benzylpenicillin/penicillins | |
| Hoy et al. | Testing the limits: Investigating the effect of tDCS dose on cognitive performance in healthy controls and patients with schizophrenia | |
| Tuten et al. | Implementation challenges. |